Suppr超能文献

腹腔镜与开腹 D3 解剖治疗 II 期或 III 期结肠癌的生存结局(JCOG0404):一项 III 期随机对照临床试验。

Survival outcomes following laparoscopic versus open D3 dissection for stage II or III colon cancer (JCOG0404): a phase 3, randomised controlled trial.

机构信息

Department of Gastroenterological and Pediatric Surgery, Oita University Faculty of Medicine, Oita, Japan.

Department of Gastroenterological and Pediatric Surgery, Oita University Faculty of Medicine, Oita, Japan.

出版信息

Lancet Gastroenterol Hepatol. 2017 Apr;2(4):261-268. doi: 10.1016/S2468-1253(16)30207-2. Epub 2017 Feb 2.

Abstract

BACKGROUND

Although benefits of laparoscopic surgery compared with open surgery have been suggested, the long-term survival of patients undergoing laparoscopic surgery for colon cancer requiring Japanese D3 dissection remains unclear. We did a randomised controlled trial to establish non-inferiority of laparoscopic surgery to open surgery.

METHODS

We did an open-label, multi-institutional, randomised, two-arm phase 3 trial in 30 hospitals in Japan. Patients aged 20-75 years who had histologically proven colon cancer; tumours located in the caecum or ascending, sigmoid, or rectosigmoid colon; T3 or deeper lesions without involvement of other organs, node stages N0-2, and metastasis stage M0; and tumour size of 8 cm or smaller were included. Only accredited surgeons did surgery as an operator or instructor. Patients were randomly assigned (1:1) preoperatively to undergo D3 resection either by an open route or a laparoscopic route, via phone call or fax to the Japan Clinical Oncology Group (JCOG) Data Center. Randomisation used a minimisation method with a biased-coin assignment according to tumour location (caecum, ascending vs sigmoid, rectosigmoid) and institution. The primary endpoint was overall survival and was analysed by intention to treat. The non-inferiority margin for the hazard ratio (HR) was set at 1·366. This study is registered with UMIN Clinical Trials Registry, number C000000105, and ClinicalTrials.gov, number NCT00147134.

FINDINGS

Between Oct 1, 2004, and March 27, 2009, 1057 patients were randomly assigned to either open surgery (n=528) or laparoscopic surgery (n=529). 5-year overall survival was 90·4% (95% CI 87·5-92·6) for open surgery and 91·8% (89·1-93·8) for laparoscopic surgery. Laparoscopic D3 surgery was not non-inferior to open surgery for overall survival (HR 1·06, 90% CI 0·79-1·41; p=0·073). 65 (13%) patients in the open surgery group and 53 (10%) patients in the laparoscopic surgery group had grade 2-4 adverse events. Grade 2-4 adverse events included diarrhoea (15 [3%] in the open surgery group vs 14 [3%] in the laparoscopic surgery group), paralytic ileus (six [1%] vs nine [2%]), and small intestine bowel obstruction (16 [3%] vs 11 [2%]). Two treatment-related deaths occurred in the open surgery group: one patient died 7 days after surgery (probably due to myocardial infarction), and one patient died from febrile neutropenia, pneumonia, diarrhoea, and gastrointestinal haemorrhage during postoperative chemotherapy.

INTERPRETATION

Laparoscopic D3 surgery was not non-inferior to open D3 surgery in terms of overall survival for patients with stage II or III colon cancer. However, because overall survival in both groups was similar and better than expected, laparoscopic D3 surgery could be an acceptable treatment option for patients with stage II or III colon cancer.

FUNDING

National Cancer Center Research and Development Fund, Grant-in-Aid for Cancer Research, and Health and Labour Sciences Research Grant for Clinical Cancer Research from the Ministry of Health, Labour and Welfare of Japan.

摘要

背景

虽然腹腔镜手术相较于开放手术具有优势已经得到了证实,但对于接受日本 D3 解剖的结肠癌患者而言,腹腔镜手术的长期生存情况仍不清楚。我们开展了一项随机对照试验,旨在证实腹腔镜手术不劣于开放手术。

方法

我们在日本的 30 家医院开展了一项开放标签、多机构、随机、两臂 3 期试验。纳入标准为:年龄在 20-75 岁之间、经组织学证实的结肠癌患者;肿瘤位于盲肠或升结肠、乙状结肠或直肠乙状结肠;T3 或更深的病变且无其他器官受累、淋巴结分期 N0-2 期和转移分期 M0 期;肿瘤大小为 8cm 或更小。只有认证的外科医生才能作为手术者或指导者进行手术。患者在术前通过电话或传真随机分配(1:1)接受开放或腹腔镜 D3 切除术,分配方案由日本临床肿瘤学组(JCOG)数据中心随机生成。随机化采用最小化方法,根据肿瘤位置(盲肠、升结肠 vs 乙状结肠、直肠乙状结肠)和机构进行偏倚硬币分配。主要终点为总生存,采用意向治疗进行分析。危险比(HR)的非劣效性边界设定为 1.366。本研究在 UMIN 临床试验注册处注册,编号为 C000000105,在 ClinicalTrials.gov 注册,编号为 NCT00147134。

结果

2004 年 10 月 1 日至 2009 年 3 月 27 日期间,共纳入 1057 例患者,随机分配至开放手术组(n=528)或腹腔镜手术组(n=529)。开放手术组的 5 年总生存率为 90.4%(95%CI,87.5%-92.6%),腹腔镜手术组为 91.8%(89.1%-93.8%)。腹腔镜 D3 手术在总生存方面并不劣于开放手术(HR,1.06;95%CI,0.79-1.41;P=0.073)。开放手术组有 65 例(13%)患者和腹腔镜手术组有 53 例(10%)患者发生 2-4 级不良事件。2-4 级不良事件包括腹泻(开放手术组 15 例[3%],腹腔镜手术组 14 例[3%])、麻痹性肠梗阻(6 例[1%],9 例[2%])和小肠肠梗阻(16 例[3%],11 例[2%])。开放手术组有 2 例与治疗相关的死亡:1 例患者术后 7 天死亡(可能死于心肌梗死),1 例患者死于术后化疗期间的发热性中性粒细胞减少症、肺炎、腹泻和胃肠道出血。

解释

对于 II 期或 III 期结肠癌患者,腹腔镜 D3 手术在总生存方面并不劣于开放 D3 手术。然而,由于两组的总生存情况相似且优于预期,腹腔镜 D3 手术可能是 II 期或 III 期结肠癌患者的一种可接受的治疗选择。

资金来源

日本国家癌症中心研究与发展基金、癌症研究资助和厚生劳动省健康与劳动科学研究资助下的临床癌症研究。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验